Literature DB >> 15549175

Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus.

J H Kuhn1, W Li, H Choe, M Farzan.   

Abstract

Cellular entry of enveloped viruses is often dependent on attachment proteins expressed on the host cell surface. Viral envelope proteins bind these receptors, and, in an incompletely understood process, facilitate fusion of the cellular and viral membranes so as to introduce the viral core into the cytoplasm. Only a small fraction of viral receptors have been identified so far. Recently, a novel coronavirus was identified as the etiological agent of severe acute respiratory syndrome (SARS). The fusion protein gene of SARS coronavirus (SARS-CoV) was cloned and characterized, and shortly thereafter, angiotensin-converting enzyme 2 (ACE2) was shown to be its functional receptor. Identification of ACE2 as a receptor for SARS-CoV will likely contribute to the development of antivirals and vaccines. It may also contribute to the development of additional animal models for studying SARS pathogenesis, and could help identify the animal reservoir of SARS-CoV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549175      PMCID: PMC7079798          DOI: 10.1007/s00018-004-4242-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  101 in total

1.  The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.

Authors:  Yang Yang; Yao Deng; Bo Wen; Huijuan Wang; Xin Meng; Jiaming Lan; George F Gao; Wenjie Tan
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

Review 2.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

3.  Relationship Between COVID-19 and Angiotensin-Converting Enzyme 2: A Scoping Review.

Authors:  Asma Shojaee; Amir Vahedian-Azimi; Fakhrudin Faizi; Farshid Rahimi-Bashar; Alireza Shahriary; Hadi Esmaeili Gouvarchin Galeh; Batool Nehrir; Paul C Guest; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Screening of JAK-STAT modulators from the antiviral plants of Indian traditional system of medicine with the potential to inhibit 2019 novel coronavirus using network pharmacology.

Authors:  Ismail Pasha; Rohini S Kavalapure; Sharad Chand; Shailendra Gurav; Pukar Khanal; Taaza Duyu; B M Patil; Yadu Nandan Dey
Journal:  3 Biotech       Date:  2021-02-08       Impact factor: 2.406

Review 5.  The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2.

Authors:  Shilei Wang; Jinlei Ye; Zhichao Kang; Hongmei Peng; Vienna Mackey; Lichun Sun
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 6.  Thrombosis in COVID-19.

Authors:  Thomas C Hanff; Amir M Mohareb; Jay Giri; Jordana B Cohen; Julio A Chirinos
Journal:  Am J Hematol       Date:  2020-09-16       Impact factor: 10.047

7.  Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted.

Authors:  Yuuki Inoue; Nobuyuki Tanaka; Yoshinori Tanaka; Shingo Inoue; Kouichi Morita; Min Zhuang; Toshio Hattori; Kazuo Sugamura
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 8.  SARS-CoV-2, ACE2 expression, and systemic organ invasion.

Authors:  Usman M Ashraf; Ahmed A Abokor; Jonnelle M Edwards; Emily W Waigi; Rachel S Royfman; Syed Abdul-Moiz Hasan; Kathryn B Smedlund; Ana Maria Gregio Hardy; Ritu Chakravarti; Lauren Gerard Koch
Journal:  Physiol Genomics       Date:  2020-12-04       Impact factor: 3.107

Review 9.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

10.  Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.

Authors:  Lanying Du; Guangyu Zhao; Chris C S Chan; Shihui Sun; Min Chen; Zhonghua Liu; Hongxiang Guo; Yuxian He; Yusen Zhou; Bo-Jian Zheng; Shibo Jiang
Journal:  Virology       Date:  2009-08-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.